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ABSTRACT
Results of allogeneic hematopoietic stem cell transplantation (HCT) to treat advanced leukemia or myelodys-
plastic syndrome (MDS) remain poor due to excessive relapse and transplant-related mortality. To improve
transplant outcome in this patient population, 43 patients (median age, 46.1 years) with high-risk or advanced
lymphoid (n  5) or myeloid malignancy (n  38) were prospectively enrolled on a pilot trial of cytoreduction
with intravenous busulfan and melphalan followed by an unmodified HLA-A, -B, and –DR1–matched related
(n  18) or unrelated (n  25) HCT. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus
and methotrexate. Thirty-four patients had > 5% blasts at the time of HCT; 12 of these had > 20% blasts.
Seventeen patients had unfavorable cytogenetics, 8 patients underwent transplantation for secondary MDS or
acute myelogenous leukemia, and 4 patients had relapsed after a previous allogeneic transplantation. Although
mucositis was the most significant regimen-related toxicity, requiring the addition of folinic acid rescue and
failure to receive all 4 doses of methotrexate in 23 patients, the nonrelapse mortality at 30 and 100 days was
low at 0% and 16%, respectively. The cumulative incidence of grade II-IV acute GVHD was 24%, and that of
extensive chronic GVHD was 7%. With a minimum follow-up of 18 months, the estimated 3-year overall
survival is 37% and the estimated disease-free survival (DFS) is 33%. For 18 patients with MDS (< RAEB-2)
or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative
potential of this regimen in patients with high-risk myeloid malignancies.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Currently more than 60% of patients undergo-
ng transplantation for acute leukemia in ﬁrst or
econd remission, de novo myelodysplastic syn-
rome (MDS) with  5% blasts, or chronic myelog-
nous leukemia (CML) in the early ﬁrst chronic (hase can achieve long-term disease-free survival
DFS) after matched related [1-7] or unrelated
6-10] hematopoietic stem cell transplantation
HCT). Unfortunately, the outcome of patients
ith more advanced disease remains poor. For pa-
ients with primary induction failure, late remission
at or beyond third continuous remission [CR3]),
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T. N. Small et al.236efractory relapse, or advanced MDS, event-free
urvival rates of 7%-36% have been reported after
ytoreduction with total body irradiation (TBI) and
yclophosphamide (Cy), TBI and etoposide (VP),
nd busulfan (BU) and Cy [11-18]. Addition of a
hird agent to the conditioning regimen to makes
uch combinations as TBI/Cy/VP [19], thiotepa/
u/Cy [20], Bu/Cy/VP [21], and anti-CD45/
BI/Cy [22], has not improved DFS in patients
ith advanced disease.
In 1996, Vey et al. [23] reported the outcome of 25
dult recipients of unmodiﬁed HLA-matched related
one marrow transplantation (BMT) who underwent
ytoreduction with 16 doses of oral busulfan (1 mg/
g/dose) followed by intravenous melphalan (140 mg/
2/day). Of these 25 patients, 16 had poor-risk disease
refractory or relapsed leukemia, blastic CML, or pri-
ary refractory lymphoma). The 4-year probability
or DFS was 31%. Long-term disease-free survivors
ncluded 2 patients with advanced acute leukemia and
patients with blastic CML. Matsuyama et al. [24]
eported a 90% 5-year DFS in 30 children (acute
yelogenous leukemia [AML], CR1 [n  18] or CR2
n 2]; acute lymphocytic leukemia [ALL], CR1 [n
] or CR2 [n  1]; or CML [n  2]] after HLA-
atched related BMT with cytoreduction with 4 days
f oral busulfan (4 mg/kg/day) and 3 days of IV mel-
halan (60 to 70 mg/m2/day). Graft-versus-host dis-
ase (GVHD) prophylaxis consisted of methotrexate
lone.
In the current trial, we evaluated the use of intra-
enous busulfan combined with melphalan, followed
y unmodiﬁed HLA-A, -B, and -DR1 unrelated or
LA-matched sibling HCT in patients with high-risk
ematologic malignancies. Intravenous rather than
ral busulfan was used due to its more consistent and
eproducible bioavailability with lower-than-expected
oxicity when evaluated in heavily pretreated patients
25,26]. GVHD prophylaxis consisting of tacrolimus
nd short-course methotrexate was used due to this
egimen’s association with lower incidence and sever-
ty of acute GVHD and decreased incidence of exten-
ive chronic GVHD [27,28]. This article describes the
utcome of 43 consecutive recipients with high-risk or
dvanced lymphoid or myeloid malignancies enrolled
n this protocol.
ETHODS
Forty-four patients or their guardians signed in-
ormed consent before initiation of cytoreduction in this
nstitutional Review Board–approved clinical research
rotocol. Eligibility criteria required a diagnosis of acute
eukemia at  CR3; infant mixed lineage leukemia; ad-
anced MDS (RAEB-1 or RAEB-2) as deﬁned by the
orld Health Organization classiﬁcation system [29]; fecondary MDS or AML; juvenile myelomonocytic leu-
emia (JMML) as deﬁned by the International JMML
orking Group [30]; or CML beyond the second
hronic phase, (accelerated or blastic phase). AnHLA-A,
B, and -DR1–matched related or unrelated donor was
equired. HLA matching was established by DNA se-
uence-speciﬁc oligonucleotide typing for HLA-A, -B,
nd -DR loci. A C-locus mismatch was present in 3
nrelated HCT recipients. One patient enrolled on pro-
ocol developed pneumonia after registration but before
tarting chemotherapy; this patient was deemed ineligi-
le due to the exclusion criteria of active infection. The
emaining 43 patients who underwent transplantation
etween January 31, 2001 and April 20, 2005 compose
ur study group.
atient Characteristics
The demographics and clinical characteristics of
he 43 patients (18 females, 25 males) are given in
ables 1 and 2. The median patient age was 46.1 years
range, 0.6-62.0 years). Eight patients (19%) were
hildren (under age 19 years at the time of transplan-
ation). Eighteen patients, 7 of whom received an
nrelated HCT, were over age 50 at the time of
ransplantation.
All patients had a high-risk or advanced hemato-
ogic malignancy (Table 2). Eight patients had sec-
ndary AML or MDS, associated with previous treat-
ent for breast cancer (n  2), ALL (n  2), Ewing’s
arcoma (n  1), Hodgkin’s disease (n  1), aplastic
nemia (n  1), or MDS (n  1). Three patients
nderwent transplantation while in CR3, including 2
hildren who had relapsed 6 months after an alloge-
eic BMT for ALL CR2 and 1 adult with AML, who
chieved CR3 after 2 courses of gemtuzumab ozo-
amicin (Mylotarg). The remaining 22 patients with
cute leukemia underwent transplantation with active
isease, including untreated AML evolving from pre-
ious MDS (n  1), primary induction failure (n  4),
efractory relapse (n  13), or untreated second re-
apse (n  4). Of the patients who underwent trans-
lantation for MDS, 2 were in refractory anemia (RA),
were in RAEB-1, and 5 were in RAEB-2 at the time
f transplantation. One patient with secondary MDS
ssociated with an 11q23 abnormality developed RA
fter treatment for Ewing’s sarcoma that progressed
o AML. This patient underwent transplantation
hile in morphologic and cytogenetic remission after
reatment with high-dose cytarabine and L-asparagi-
ase.
At the time of transplantation, 34 patients had 5%
one marrow blasts. The median blast count of these 34
atients was 16% (range, 5%-81%). Cytogenetic analy-
es were evaluable in all 43 patients (Table 2) and were
bnormal in 53% of them. Seventeen patients had un-
avorable cytogenetics [31], deﬁned as abnormalities of
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HCT in advanced leukemia 237hromosome 5, 7, 11q23, or trisomy 8 and/or 3 chro-
osomal abnormalities (Table 2).
reparative Regimen
Patients received intravenous busulfan (Busulfex;
rphan Medical Co), a total of 16 doses infused every
hours for 4 days, followed by intravenous melphalan
45 mg/m2/day) for 3 days. The initial busulfan dosage
as based on patient age. Patients age 4 and younger
eceived 1 mg/kg/dose; those over 4 years, 0.8 mg/kg/
ose. Based on pharmacokinetic studies, the protocol
as subsequently amended to adjust the initial dose to
.1 mg/kg/dose in patients weighing  12 kg and 0.8
g/kg/dose for those weighing  12 kg. First-dose
able 1. Patient and Donor Characteristics
All P
(n 
ge (years), median (range) 46.0 (0
ex 18 F
LL
CR3 2, prior allo
Refractory first relapse
Refractory second relapse
ML 2
CR3
Untreated AML, post-MDS
Primary Induction failure
Refractory first relapse
Untreated second relapse
Refractory second relapse
DS/myeloproliferative disorder (MPD) 1
Secondary MDS, RA, AML, CR1
RA/RA (prior RAEB-2) 1/
RAEB-1
RAEB-2
JMML
CML (acc/blast crisis, acc) 1/
Ph-myeloproliferative disorder
rior allogeneic HCT
reatment-related
tem cell source
Bone marrow 2
Peripheral blood 1
atient/donor CMV serology
Negative/negative 1
Negative/positive
Positive/negative
Positive/positive 1
able 2. Causes of Death
Related Unrelated Total
elapse 8 6 14
oxicity 1 (IP) 3 (VOD, IP, TRALI) 4
VHD 2 3 5
nfection 1 (CMV IP) 1 (sepsis) 2
raft failure 0 1 1
P indicates interstitial pneumonia; TRALI, transfusion-related
2acute lung injury [35].harmacokinetics were performed at the Fred
utchinson Cancer Research Center using high-per-
ormance liquid chromatography–mass spectrometry.
he busulfan dose was adjusted to reach a steady-state
evel of 600-900 ng/mL, with the desired level closer
o 900 ng/mL. One patient who received the 16-dose
ourse of busulfan was found to have an elevated
usulfan level (1080 ng/mL) after completing therapy,
nd thus was given only 80% of the total melphalan
ose. Due to an early graft failure in the trial after an
nrelated donor HCT, equine antithymocyte globulin
ATG) (15 mg/kg/day, days 4 and 3) was added to
he preparative regimen in those patients receiving
nrelated donor transplants.
VHD Prophylaxis and Evaluation
GVHD prophylaxis consisted of 4 doses of intra-
enous methotrexate (15 mg/m2 on day1, 10 mg/m2
n days 3, 6, and 11) and continuous-infusion
ntravenous tacrolimus (0.03 mg/kg/24 hours) starting
n day 1. This protocol was amended after the ﬁrst
0 patients were accrued to include folinic acid rescue
very 6 hours for 4-6 doses, starting 24 hours after
ach methotrexate dose. Folinic acid was discontinued
Related Donor
(n  18)
Unrelated Donor
(n  25)
) 50.5 (7.0-62.0) 37.0 (0.6-61.0)
8 F/10 M 10 F/15 M
3 2
n  2) 2 0
1 1
0 1
12 8
0 1
1 0
1 3
6 1
2 2
2 1
4 11
0 1
0 0
2 2
2 3
0 3
0 2
0 1
3 1
1 6
13 14
5 11
8 11
3 2
1 6
7 5atients
43)
.6-62.0
/25 M
5
-BMT (
2
1
0
1
1
4
7
4
3
8
1
1
4
5
3
1
1
4
7
7
6
9
5
74 hours before the subsequent methotrexate dose.
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T. N. Small et al.238cute GVHD was deﬁned as any GVHD occurring
100 days posttransplantation and was graded ac-
ording to the Glucksberg criteria [32]. Chronic
VHD (ie, GVHD occurring 100 days post-HCT)
as graded as limited or extensive according to the
riteria of Sullivan et al. [33].
ngraftment, Graft Failure, and Donor Chimerism
Engraftment was deﬁned as the ﬁrst of 3 consec-
tive days of an absolute neutrophil count (ANC) of
500 cells/L. Primary graft failure was deﬁned as
ailure to achieve an ANC of 500 cells/L by day 28
fter HCT. Platelet engraftment was deﬁned as an
ntransfused platelet count of  50,000/L for at
east 3 consecutive days. Bone marrow aspirates were
btained at regular intervals posttransplantation to
ssess remission chimeric status. Bone marrow donor–
ost chimerism was assessed by polymerase chain re-
ction analysis of short tandem repeats using primers
5S818, D13S317, D7S820, and D16S539.
upportive Care
All patients underwent transplantation in reverse
solation in a single room with ﬁltered air. Seizure
rophylaxis with phenytoin was administered before
he ﬁrst busulfan dose and continued for 24 hours
fter the last busulfan dose. Herpes simplex virus,
ungal, and Pneumocystis carinii pneumonia prophylaxis
as given to all patients as described previously [2].
ytomegalovirus (CMV)-seropositive patients or
hose with a CMV-seropositive donor were followed
or CMV antigenemia and received treatment with
anciclovir or foscarnet for positive antigenemia ( 1
ell positive/slide). Neutropenic patients with persis-
ent fever despite 72 hours of broad-spectrum antibi-
tics received empiric antifungal therapy. All recipi-
nts of an unrelated transplant and those recipients of
n HLA-matched related HCT whose serum IgG
evel was  500 ng/dL received monthly intravenous
amma globulin (400 mg/kg/dose) for at least 3
onths posttransplantation.
iostatistics
Analyses were performed as of September 1, 2006.
he Kaplan-Meier estimate was used to compute the
verall survival (OS) and DFS probabilities. The cu-
ulative incidence function was used to estimate the
robability of the time to relapse, nonleukemic mor-
ality, and GVHD. The equality of the OS and DFS
ates between groups was assessed using the log-rank
tatistic. Gray’s statistic was used to test the equality of
he relapse, nonleukemic mortality, and GVHD rates
etween groups [34]. eESULTS
usulfan Levels
Pharmacokinetic analyses were performed for 42
f the 43 patients. The median steady-state level
chieved after the ﬁrst dose was 770 ng/mL (range,
70-1199 ng/mL). In patients under age 19, the me-
ian initial busulfan steady-state level was 535 ng/mL
range, 370-1180) ng/mL; in those age 19 and older, it
as 799 ng/mL (range, 566-1199 ng/mL). The initial
usulfan level was below the target level ( 600 ng/
L) in 75% of children and 9% of adults and above
he target level ( 900 ng/dL) in 12.5% of children
nd 30% of adults. The median initial busulfan level
n patients who subsequently relapsed (790 ng/dL) did
ot signiﬁcantly differ from that in patients who did
ot relapse (761 mg/mL).
raft Characteristics
Twenty-seven patients received a BM transplant
rom an HLA-matched related (n  15) or unrelated
onor (n  12), and 16 patients received a peripheral
lood stem cell (PBSC) transplant from an HLA-
atched related (n  4) or unrelated donor (n  12).
he choice of PBSC or BM was based on the donor’s
reference. The median (range) total nucleated cell
ose was 2.14 (0.4-9.1) 108/kg in BM recipients and
4.2 (2.24-605.0)  108/kg in PBSC recipients.
ngraftment
Forty-one of the 43 patients engrafted at a median
f 15 days (range, 10 to 24 days). Primary graft failure,
eﬁned as failure to achieve an ANC of 500 cells/L
y day 28, occurred in 2 children with MDS who
eceived an unrelated BMT. In the absence of ATG, 1
f 4 recipients of an unrelated HCT failed to engraft.
n contrast, only 1 of the 21 patients who received
quine ATG before an unrelated HCT experienced
raft failure. Twenty-ﬁve of the 27 BM recipients
ngrafted at a median of 18 days (range, 11-24 days);
ll PBSC recipients engrafted, at a median of 13 days
range, 10-23 days). Among the 41 patients who en-
rafted, the time to ANC  500 was more rapid in
BSC recipients than in BM recipients (P  .001).
he median time to achieve an untransfused platelet
ount of 50,000 was 28 days (19.5 days after PBSCT
nd 32 days after BMT; P  .13).
emission Induction
CR after transplantation was deﬁned as  5%
arrow blasts, absence of circulating blasts, lack of
hromosomal abnormalities, and donor cell engraft-
ent. Three patients were not evaluable for remission
nduction due to graft failure (n 2) or failure to have
day 30 bone marrow aspiration despite peripheral
ngraftment. The rate of CR in the 40 evaluable
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HCT in advanced leukemia 239atients was 100%, including all patients with active
isease at the time of transplantation.
egimen-Related Toxicity
The most signiﬁcant toxicities associated with this
rotocol were mucositis and renal insufﬁciency. Forty
atients developed grade III mucositis according to
he BMT CTC Version 2.0 (Appendix V, BMT-Spe-
iﬁc Events), and 2 patients developed grade IV mu-
ositis requiring mechanical ventilation for airway
rotection. Due to signiﬁcant mucositis, 21 patients
eceived only 3 doses of methotrexate, and 2 patients
eceived 2 doses. Six patients developed grade III renal
oxicity (creatinine  3-6 times the upper limit of
ormal). Four patients developed reversible renal fail-
re due to nephrotoxic drugs (n  2), septic shock
n  1), or severe hemolysis (n  1). Two patients
eveloped veno-occlusive disease (VOD) (4.7%);
hese were 2 of the 5 patients in this study who had
eceived gemtuzumab ozogamicin before transplanta-
ion.
cute GVHD
A total of 41 patients were evaluable for the de-
elopment of acute GVHD. Ten patients developed
cute grade II-IV GVHD (3 grade II, 5 grade III, and
grade IV). The 100-day cumulative incidence of
cute grade II-IV GVHD was 0.24. There was no
igniﬁcant difference in the incidence of grade II-IV
cute GVHD between recipients of HLA-matched
ibling transplants (4/18; 22%) and unrelated trans-
lants (6/23; 26%).
hronic GVHD
Twenty-nine engrafted patients survived more
han 100 days after related (n  14) or unrelated (n 
5) HCT and were evaluable for chronic GVHD.
imited chronic GVHD occurred in 9 patients, and
xtensive chronic GVHD developed in 2 patients.
ne patient developed an isolated but fatal acute he-
atic variant of GVHD 9 months after an HLA-
atched related PBSC transplant (PBSCT). Chronic
VHD occurred in 7 of 14 recipients of an HLA-
atched related HCT and in 4 of 15 recipients of an
nrelated HCT (P  .57).
elapse
To date, 17 patients have relapsed (Figure 1).
elapse occurred at a median of 9.8 months (range,
.6-29.5 months) posttransplantation. The cumulative
ncidence of relapse at 3 years was 0.36. For patients
ho received  20% or  20% BM blasts, the cumu-
ative incidence of relapse at 3 years was 0.29 and 0.75,
espectively (P  .0009). Four of 5 patients who un-
erwent transplantation for ALL relapsed, including 2
atients whose disease recurred after a previous allo- Heneic HCT and 2 of 3 patients who underwent trans-
lantation during a refractory relapse. Thirteen of 38
34%) patients who underwent transplantation for a
yeloid malignancy (AML, MDS, or myeloprolifera-
ive disease (MPD)) relapsed. Three of 18 (17%) pa-
ients transplanted for MDS/MPD recurred at 5.4,
.6, and 6.7 months post-HCT. Ten of 20 patients
ho underwent transplantation for AML (1 in CR3
nd 19 in active disease) relapsed at a median of 3.7
onths (range, 2.6-22.0 months) post-HCT.
S and DFS
The 3-year probability of OS and DFS for the
ntire cohort was 0.37 (95% conﬁdence interval
CI]  0.24-0.57) and 0.33 	 0.08 (95% CI 
.21-0.51), respectively (Figure 2A). The estimated
-year DFS was 0.39 in patients who received 
0% (n  31) and 0.17 in those who received 
0% (n  12) blasts (Figure 2B), respectively (P 
09). Among the patients who underwent transplan-
ation for a myeloid malignancy, the 3-year DFS
as 0.61 for patients with MDS ( 20%) or a
yeloproliferative disorder and 0.13 in the 20 pa-
ients with AML, 95% of whom had active disease at
he time of HCT (P  .01) (Figure 3).
At a median follow-up of 44 months (range, 18.1-
7.9 months), 17 patients were alive without disease,
4 in CR. Three patients relapsed and were salvaged
y a subsequent transplantation. One relapse occurred
n a child with MDS (RAEB, monosomy 7) who re-
ected an unrelated BMT and engrafted after a T-cell–
epleted HLA-mismatched maternal PBSCT. He re-
apsed 7 months after the latter transplant and was
live without disease 46 months after his third
Figure 1. Cumulative incidence of recurrence.CT, a second T cell depleted, HLA-mismatched
m
m
r
m
a
b
p
p
b
H
u
p
a
k
b
u
K
C
m
p
1
2
f
l
(
C
OS and
T. N. Small et al.240aternal PBSCT. The second patient is a 49-year-old
ale who underwent transplantation for AML in ﬁrst
efractory relapse (52% blasts), who relapsed 16
onths after an HLA-matched sibling HCT and was
live without disease 43 months after a nonmyeloa-
lative transplant from his original donor. The third
atient is a 50-year-old male who underwent trans-
lantation for AML in ﬁrst refractory relapse (20%
one marrow blasts) who relapsed 22 months post-
CT. He was alive in CR 6 months after a second
nmodiﬁed HCT from his primary donor. The only
atient treated for ALL who survived disease-free is
n adult who underwent transplantation for natural
iller cell positive ALL in refractory ﬁrst relapse (59%
Figure 2. (A) OS and DFS (n  43). (B)lasts) who was alive and well 58.0 months after an anrelated PBSCT. All surviving patients had a
arnofsky or Lansky score of  80.
ause of Death
Twenty-six patients died, at a median of 4.9
onths (range, 1.7-41.5 months) post-HCT. The
rimary causes of death (Table 2) were relapse (n 
4), GVHD (n  5), toxicity (n  4), infection (n 
), and graft failure (n  1). Fatal toxicity took the
orm of VOD (n  1), transfusion-related acute
ung injury (n  1), and idiopathic pneumonitis
n  2). Fatal infectious complications included
MV pneumonitis (n  1) and polymicrobial sepsis
DFS by blast count  20% or  20%.ssociated with septic shock and multiorgan failure
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HCT in advanced leukemia 241n  1). Nonrelapse mortality for the 43 patients
as 0.28 (Figure 4).
ISCUSSION
The aim of this pilot trial was to assess the anti-
eukemic potential of cytoreduction with intravenous
usulfan and melphalan, followed by unmodiﬁed allo-
eneic HCT in patients with an advanced or high-risk
ematologic malignancy. We also sought to deter-
ine the incidence of transplant-related morbidity
nd mortality associated with this regimen, as well as
he efﬁcacy of tacrolimus and methotrexate for pre-
enting GVHD. Despite the extremely high-risk na-
ure of this patient population, as of the time of this
eport, 17 of 43 patients were alive and free of disease,
igure 3. OS (upper) and DFS (lower) in the 38 patients with a
yeloid malignancy.ith 14 in CR. Patients with an advanced or high-riskyeloid malignancy (median age, 49.5 years) achieved
n estimated 42% OS and 35% DFS at 3 years with a
elapse rate of 34%. Of the 5 patients with an ad-
anced or refractory lymphoid malignancy, 3 of whom
nderwent transplantation while in refractory ﬁrst or
econd relapse and 2 of whom relapsed after a previ-
us allogeneic HCT, only 1 survived in CR. Although
atients with lymphoid malignancies composed a
mall subset of the total number of patients who un-
erwent transplantation in this trial, these results are
imilar to those of larger studies reported in the liter-
ture [36,37].
Despite the inclusion of heavily pretreated pa-
ients, the nonrelapse mortality at was 0 at 30 days,
6% at 100 days, and 28% at 365 days, and the
ncidence of VOD was  5%. VOD was observed in
patients who received gemtuzumab before trans-
lantation [38]. A similarly low incidence of VOD has
een observed in allogeneic transplant recipients
iven other regimens that include intravenous busul-
an [26,39]. However, several modiﬁcations to the
rotocol were needed to reduce regimen-related tox-
city. Folinic acid rescue was added after each dose of
ethotrexate to decrease the severity of mucositis.
acrolimus was titrated to achieve levels of 5 to 10
g/mL, to reduce renal toxicity, and ATG was in-
luded in the pretransplantation conditioning regimen
o prevent graft failure after an unrelated HCT. De-
pite these changes, the incidence of grade II-IV acute
VHD and chronic GVHD was low in our series.
lthough the relative contribution of pretransplanta-
ion ATG and posttransplantation methotrexate and
acrolimus cannot be ascertained, the observed inci-
ences of acute (24%) and extensive chronic GVHD
7%) are consistent with those in reports demonstrat-
ng the superiority of tacrolimus and short-courseFigure 4. Nonleukemic mortality.
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T. N. Small et al.242ethotrexate in preventing severe acute and extensive
hronic GVHD compared with cyclosporine A and
ethotrexate [27,28]. These data also support previ-
us studies demonstrating that folinic acid rescue in
ethotrexate-containing regimens is not associated
ith an increased risk of GVHD [40,41].
The fact that each of the 40 evaluable patients
chieved remission after cytoreduction with busulfan
nd melphalan and that 14 of the 41 patients who
ngrafted are alive and disease-free attests to the an-
ileukemic activity of this regimen even in patients
ith refractory disease. As other studies have noted,
he percentage of BM blasts at the time of HCT was
n important predictor of DFS [13,15,18,36-38,42].
learly, interventions are needed to further improve
FS in these high-risk patients. Although nonmyeloa-
lative (NMA) or reduced-intensity cytoreductive
RIC) regimens have been associated with a lower
onrelapse mortality, most series have not shown an
mproved DFS in patients with advanced hematologic
alignancies [43]. A retrospective study by the Euro-
ean Group for Blood and Marrow Transplantation
44] comparing outcomes of patients over age 50 years
ith advanced AML ( CR2) given reduced-intensity
r myeloablative therapy followed by an HLA-
atched sibling transplant demonstrated no signiﬁ-
ant difference in 2-year estimated DFS between the 2
roups (23 	 5 for RIC vs 21 	 4 for myeloablative).
lthough cytoreduction with a RIC regimen consist-
ng of once-daily intravenous busulfan and ﬂudarabine
ollowed by unmodiﬁed HCT was associated with a
-year estimated DFS of 75% in patients who under-
ent transplantation for AML or MDS in CR and
4% in those with active disease [39]. In 31 patients
iven a NMA conditioning regimen for treatment of
n advanced myeloid leukemia ( CR1) or advanced
DS, Alyea et al. [45] reported an estimated 2-year
S of 28%, compared with 16% for patients who
eceived myeloablative therapy (P  .08). Patients
ith chemotherapy-resistant or rapidly growing leu-
emias likely will derive less beneﬁt from NMA or
IC, due in part to the inability of these regimens to
nduce signiﬁcant disease control before generation of
functional graft-versus-leukemia (GVL) effect. Scott
t al. [46] compared transplant outcome after myeloa-
lative therapy with targeted Bu/Cy (n  112) versus
MA cytoreduction (200 cGy TBI, with [n  36] or
ithout [n  2] ﬂudarabine) in patients over age 40
ith MDS or AML with trilineage dysplasia. Eligibil-
ty criterion for NMA in this study was  10% blasts
t the time of HCT. Despite the fact that the patients
eceiving a myeloablative conditioning regimen had
ore advanced disease before transplantation (as mea-
ured by peak International Prognostic Scoring Sys-
em risk score), there was no statistical difference in
rogression-free survival at 3 years between the 2
ohorts (44% vs 27%) and, surprisingly, no differencen NRM (32% for myeloablative vs 39% for NMA).
lthough clinically extensive chronic GVHD occurred
n 62% of HCT recipients who received myeloablative
onditioning and in 55% of those who received NMA
onditioning, disease progression remained the primary
ause of death in both groups [46].
Although further intensiﬁcation of pretransplan-
ation cytoreduction has been used in an attempt to
mprove DFS in patients with poor-risk disease, it has
enerally resulted in an increase in nonrelapse mor-
ality, negating any beneﬁcial effect on disease control
19-21]. In contrast, prophylactic immunotherapy
ith donor lymphocytes [47], donor-derived natural
iller cells in Kir ligand–mismatched patients [48],
nd/or cytotoxic T cells directed against antigens dif-
erentially expressed on leukemic cells (eg, WT1
49,50] or PR-1 [51]) might permit establishment of
n effective GVL effect early after transplantation
ithout increasing the risk of GVHD or the need for
xtended immunosuppressive therapy. The median
ime to relapse in this study (9.8 months) and the high
ate of remission induction support the use of this
ytoreductive regimen as a platform on which to test
doptive immunotherapy strategies. In addition, for
atients with less advanced myeloid malignancies who
annot tolerate TBI and/or cyclophosphamide due to
oung age, previous radiotherapy, cardiac dysfunc-
ion, or hemorrhagic cystitis, this regimen offers an
lternative that merits further exploration.
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